Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

KU Medical Center to Lead $7.5 Million Male Contraceptive Research and Drug Development Program

Published: Thursday, April 12, 2007
Last Updated: Thursday, April 12, 2007
Bookmark and Share
The University will use the NIH grant to establish a multi-institutional organization that will work to develop new non-hormonal, reversible male contraceptive agents for drug production.

A researcher at the University of Kansas Medical Center has been awarded more than $7.5 million in funding from the National Institutes of Health to lead a team, including researchers at seven universities, in a collaborative effort to develop male contraceptives.

This five-year grant will establish the Interdisciplinary Center for Male Contraceptive Research and Drug Development, a multi-institutional organization that will work to develop new non-hormonal, reversible male contraceptive agents for drug production.

The center will not only consist of research teams at KU Medical Center and KU-Lawrence, but also collaborators across the country at the University of Minnesota, Duke University, the University of California-San Fransisco, Robert Wood Johnson Medical School, and the University of Medicine and Dentistry of New Jersey.

Funding for the center was awarded by the Contraception & Reproductive Health Branch of the National Institute of Child Health and Human Development.

The center will be directed by Joseph Tash, PhD, an associate professor of molecular and integrative physiology at KUMC, and associate director, Dr. Gunda Georg, Chair of Medicinal Chemistry at University of Minnesota. Tash, Georg, and a team of researchers at KUMC and KU Lawrence, have been conducting NIH-funded research, designing and testing male contraceptive agents, for more than five years.

Their work has lead to the development of some promising chemical compounds, such as Gamendazole, one of the most potent new oral anti-spermatogenic agents identified to date. Under this grant, research will continue on Gamendazole as well as exploring new lead compounds.

Tash said the group intends to take a multidisciplinary approach, focusing on several chemical compounds, and proteins that regulate testes function so that mature sperm are not produced. They are also concentrating on chemical agents that may temporarily deactivate enzymes so that sperm development is prevented or sperm are immobilized so the egg remains unfertilized. To identify new lead compounds, the center will utilize High Throughput Screening and proteomics to test hundreds of thousands of compounds.

While High Throughput Screening (HTS) technology is more common in private industry, KU is one of the few universities in the nation to have such a facility, which Tash said is important since many pharmaceutical companies have curtailed their research and development in male contraception. Without the HTS lab, screening hundreds of thousands of compounds could take years, but with the technology, screening time is dramatically reduced to weeks.

The research program in this center will go beyond identifying new protein targets involved in regulation of male fertility, and begin cutting edge drug discovery and design. The scientists involved in the research have a record of success in providing NIH with highly promising reversible non-hormonal male contraceptive agents.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Blocking Previously ‘Undruggable’ Cancer Protein
Researchers from the University of Kansas have found molecular that block previously ‘undruggable’ protein tied to cancer’s onset.
Monday, April 13, 2015
Cancer Treatment with KU Origins Enters Second Clinical Trial
Cleave Biosciences has begun a Phase 1 clinical trial to evaluate CB-5083.
Thursday, February 05, 2015
KanPro Research Begins Work as 25th KU Startup Company
New startup company designed to tackle protein production.
Friday, June 20, 2014
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Nanoparticles Target, Transform Fat Tissue
Nanoparticles designed to target white fat and convert it to calorie-burning brown fat slowed weight gain in obese mice without affecting food intake. This proof-of-concept work could lead to new therapies to treat obesity.
New Cancer Fighters Emerge From Lab
Rice University lab simplifies total synthesis of anti-cancer agent.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!